Tectonic Therapeutic Free Cash Flow (FCF) History (TECX)
Tectonic Therapeutic reported −$60.3M in free cash flow for fiscal 2025, a decrease of $1.1M from the previous fiscal year.
View full Tectonic Therapeutic company overviewTectonic Therapeutic free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$60.3M | −$1.1M | — | — |
| 2024 | 2024-12-31 | −$59.2M | −$18.3M | — | — |
| 2023 | 2023-12-31 | −$41.0M | $56.5M | — | — |
| 2022 | 2022-12-31 | −$97.5M | $3.0M | — | — |
| 2021 | 2021-12-31 | −$100.5M | −$506,000 | — | — |
| 2020 | 2020-12-31 | −$100.0M | −$30.7M | — | — |
| 2019 | 2019-12-31 | −$69.3M | −$29.8M | — | — |
| 2018 | 2018-12-31 | −$39.5M | −$22.7M | — | — |
| 2017 | 2017-12-31 | −$16.8M | — | — | — |
Tectonic Therapeutic quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$21.5M | −$6.8M | — | — |
| Q1 2026 | 2026-03-31 | −$18.4M | −$5.3M | — | — |
| Q4 2025 | 2025-12-31 | −$14.5M | $2.4M | — | — |
| Q3 2025 | 2025-09-30 | −$18.0M | $1.8M | — | — |
| Q2 2025 | 2025-06-30 | −$14.7M | −$1.3M | — | — |
| Q1 2025 | 2025-03-31 | −$13.1M | −$3.8M | — | — |
| Q4 2024 | 2024-12-31 | −$16.8M | −$5.1M | — | — |
| Q3 2024 | 2024-09-30 | −$19.8M | −$11.3M | — | — |
| Q2 2024 | 2024-06-30 | −$13.4M | −$12.9M | — | — |
| Q1 2024 | 2024-03-31 | −$9.3M | $11.0M | — | — |
| Q4 2023 | 2023-12-31 | −$11.7M | $12.0M | — | — |
| Q3 2023 | 2023-09-30 | −$8.5M | $8.0M | — | — |
| Q2 2023 | 2023-06-30 | −$473,000 | $28.8M | — | — |
| Q1 2023 | 2023-03-31 | −$20.3M | $7.8M | — | — |
| Q4 2022 | 2022-12-31 | −$23.7M | $3.1M | — | — |
| Q3 2022 | 2022-09-30 | −$16.5M | $8.6M | — | — |
| Q2 2022 | 2022-06-30 | −$29.3M | −$8.1M | — | — |
| Q1 2022 | 2022-03-31 | −$28.0M | −$592,000 | — | — |
| Q4 2021 | 2021-12-31 | −$26.7M | $3.8M | — | — |
| Q3 2021 | 2021-09-30 | −$25.1M | −$197,000 | — | — |
| Q2 2021 | 2021-06-30 | −$21.2M | $312,000 | — | — |
| Q1 2021 | 2021-03-31 | −$27.5M | −$4.4M | — | — |
| Q4 2020 | 2020-12-31 | −$30.6M | −$11.2M | — | — |
| Q3 2020 | 2020-09-30 | −$24.9M | −$11.4M | — | — |
| Q2 2020 | 2020-06-30 | −$21.5M | −$3.1M | — | — |
| Q1 2020 | 2020-03-31 | −$23.0M | −$4.9M | — | — |
| Q4 2019 | 2019-12-31 | −$19.3M | −$7.4M | — | — |
| Q3 2019 | 2019-09-30 | −$13.5M | −$560,000 | — | — |
| Q2 2019 | 2019-06-30 | −$18.4M | −$10.0M | — | — |
| Q1 2019 | 2019-03-31 | −$18.1M | −$11.8M | — | — |
| Q4 2018 | 2018-12-31 | −$11.9M | −$8.6M | — | — |
| Q3 2018 | 2018-09-30 | −$12.9M | — | — | — |
| Q2 2018 | 2018-06-30 | −$8.4M | — | — | — |
| Q1 2018 | 2018-03-31 | −$6.2M | — | — | — |
| Q3 2017 | 2017-09-30 | −$3.3M | — | — | — |
Tectonic Therapeutic free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$100.0M to −$60.3M, a net increase of $39.7M. Tectonic Therapeutic's latest reported quarter, Q2 2026, generated −$21.5M in free cash flow, a decrease of $6.8M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tectonic Therapeutic filings at SEC.gov ↗